This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Isatuximab parenteral

Updated 2 Feb 2023 | Isatuximab


Infusions of isatuximab.

These products have been produced by recombinant technology using Chinese Hamster Ovary (CHO) cell lines.

Drugs List

  • isatuximab 100mg/5ml concentrate for solution for infusion vial
  • isatuximab 500mg/25ml concentrate for solution for infusion vial
  • SARCLISA 100mg/5ml concentrate for solution for infusion vial
  • SARCLISA 500mg/25ml concentrate for solution for infusion vial
  • Therapeutic Indications


    Multiple myeloma: resistant to one previous therapy
    Relapsed and refractory multiple myeloma

    In combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.

    In combination with carfilzomib and dexamethasone for the treatment of adult patients with MM who have received at least one prior therapy.


    Whilst the doses stated below are those recommended by the manufacturer, local cancer network protocols for the relevant indication should be consulted.


    Dexamethasone: 40mg oral or intravenous (or 20mg for patients 75 years or older), as part of the premedication and the backbone treatment, before isatuximab and pomalidomide administration.
    20mg intravenous, as part of the premedication and the backbone treatment, before isatuximab and carfilzomib administration on the days of isatuximab and/or carfilzomib infusions and 20mg oral on the other days. Paracetamol: 650mg to 1000mg oral. Diphenhydramine: 25mg to 50mg intravenous or oral. Intravenous infusion is preferred for at least the first 4 infusions.
    The recommended premedication treatment should be administered 15-60 minutes prior to starting the isatuximab infusion. Patients who do not experience an infusion reaction upon their first 4 administrations of isatuximab may have their need for subsequent premedication reconsidered.
    Isatuximab infusion
    Cycle 1 10mg/kg body weight on days 1, 8, 15 and 22 (weekly).
    Cycle 2 and beyond 10mg/kg body weight on days 1 and 15 of each 28 day cycle (every 2 weeks).

    Additional Dosage Information

    Infusion rates
    First infusion: 250ml infused at initial rate of 25ml/hour. If there is an absence of an infusion reaction for 60 minutes, the infusion rate can be increased in 25ml/hour increments every 30 minutes, until a maximum rate of 150ml/hour. Second infusion: 250ml infused at initial rate of 50ml/hour. If there is an absence of an infusion reaction for 30 minutes, the infusion rate can be increased by 50ml/hour increments for 30 minutes, then increase by 100ml/hr every 30 minutes until a maximum rate of 200ml/hour. Subsequent infusions: 250ml infused at initial rate of 200ml/hour. Grade 2 infusion reactions: Interrupt infusion and administer additional symptomatic medicinal products. After improvement to grade 1 or lower, infusion may be resumed at half the initial infusion rate. If symptoms do not recur after 30 minutes, the infusion rate may be increased to the initial rate, then increased incrementally as stated above. If symptoms do not resolve rapidly or do not improve to grade 1 or lower after interruption, or persist or worsen despite appropriate medical products, or require hospitalisation or are life-threatening (grade 3 or greater), treatment should be permanently discontinued.


    Children under 18 years

    Precautions and Warnings

    Patients over 85 years
    Moderate hepatic impairment

    Pre-medicate with a corticosteroid, antihistamine and paracetamol
    Premedication with anti-infective recommended during treatment
    Prophylactic G-CSF should be considered
    Treatment to be initiated and supervised by a specialist
    Consult local policy on the safe use of anti-cancer drugs
    Record name and batch number of administered product
    Resuscitation facilities must be immediately available
    Staff: Not to be handled by pregnant staff
    Monitor full blood count regularly
    Monitor patient closely for haemolysis
    Monitor patient for infusion-associated reactions (IARs)
    Monitor patients for development of second primary malignancies
    Monitor vital signs and ECG every day during infusion
    Advise patient to report symptoms of infection immediately
    Advise patients at risk of neutropenia to report any signs of infection
    Interrupt therapy/reduce infusion rate if infusion-related reactions occur
    Test interference: May cause false positive Coombs test
    May interfere with antibody tests
    May interfere with certain laboratory measurements
    Discontinue permanently if life threatening infusion reactions occur
    Female: Contraception required during & for at least 5 months after therapy

    Pregnancy and Lactation


    Isatuximab is contraindicated during pregnancy.
    The manufacturer suggests that the use of isatuximab is not recommended in pregnancy. There are no data on the safety of isatuximab in pregnant women and no animal reproduction toxicity studies have been conducted. Immunoglobulin G1 monoclonal antibodies are known to cross the placenta after the first trimester of pregnancy.


    Isatuximab is contraindicated during breastfeeding.
    The manufacturer recommends that women must discontinue breastfeeding during isatuximab treatment. It is not known whether isatuximab is excreted in human breast milk, although immunoglobulins are known to be excreted in breast milk, therefore a risk to the breastfeeding infant cannot be excluded. A decision must be made whether to discontinue breastfeeding or discontinue from isatuximab therapy.

    Side Effects

    Anaphylactic reaction
    Atrial fibrillation
    Back pain
    Decreased appetite
    Febrile neutropenia
    Infusion related reaction
    Skin carcinoma
    Squamous cell carcinoma
    Upper respiratory tract infection
    Weight loss


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management. The following number will direct the caller to the relevant local centre (0844) 892 0111 Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2020

    Reference Sources

    NICE Evidence Services Available at: Last accessed: 21 July 2021

    Summary of Product Characteristics: Sarclisa 20mg/ml concentrate for solution for infusion. Sanofi Genzyme. Revised February 2022.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.